Recursion Pharmaceuticals (RXRX) Payables (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Payables data on file, last reported at $20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 18.89% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $20.3 million (down 18.89% YoY), and the FY2025 full-year result was $18.1 million, down 16.17% from the prior year.
• Payables for Q1 2026 stood at $20.3 million, up from $18.1 million in the prior quarter.
• Across five years, Payables topped out at $25.1 million in Q1 2025 and bottomed at $2.3 million in Q3 2024.
• The 5-year median for Payables is $4.9 million (2023), against an average of $9.6 million.
• The widest annual swing landed in 2024, when Payables tumbled 54.44%; it then soared 516.59% in 2025.
• A 5-year view of Payables shows it stood at $4.7 million in 2022, then retreated by 14.71% to $4.0 million in 2023, then jumped by 441.14% to $21.6 million in 2024, then decreased by 16.17% to $18.1 million in 2025, then rose by 12.31% to $20.3 million in 2026.
• The last three Payables figures came in at $20.3 million (Q1 2026), $18.1 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.

Peer Comparison